<DOC>
	<DOCNO>NCT00194896</DOCNO>
	<brief_summary>The purpose research test whether one treatment superior another management type 1.5 diabetes . Specifically test recently diagnose antibody positive type 2 diabetic patient determine whether treatment rosiglitazone result great preservation beta cell function compare treatment glyburide .</brief_summary>
	<brief_title>Preferred Treatment Type 1.5 Diabetes</brief_title>
	<detailed_description>Type 1 diabetes Type 2 diabetes different underlie pathophysiologic process . The disease process classical Type 1 diabetes autoimmune destruction pancreatic beta cell . In contrast , disease process classical Type 2 diabetes autoimmune nature , decrease sensitivity insulin action central disease process , poorly understood non-inflammatory beta cell lesion occur diminishes insulin secretion . In clinical practice , diagnosis Type 1 versus Type 2 diabetes make phenotypically use variable age onset , apparent abruptness onset hyperglycemia , presence ketosis , degree obesity ( especially central intra abdominal ) , prevalence autoimmune disease , apparent need insulin replacement . This clinical distinction Type 1 versus Type 2 diabetes recognize imperfect . There also third group individual , phenotypically usually like classic Type 2 diabetic positive one autoantibodies commonly see Type 1 disease process , namely islet cell antibody ( ICA ) and/or insulin autoantibody ( IAA ) and/or autoantibody glutamic acid decarboxylase ( GAD Ab ) and/or autoantibody tyrosine phosphatase islet cell autoantibody 512 ( IA 2 Ab ) . These patient , autoantibody positive [ Ab ( + ) ] Type 2 Type 1.5 diabetes , focus study . Compared antibody negative Type 2 diabetic , patient Type 1.5 diabetes rapid decline beta cell function , fail sulfonylurea therapy require insulin therapy earlier ( 4-13 ) . Hypothesis : Rosiglitazone treatment ameliorate slow underlying disease process antibody positive Type 2 diabetes . Patients meet inclusion criterion come baseline visit . The nature study explain informed consent obtain . A fasting blood sample obtain autoantibody , glucose , C peptide proinsulin molecule ( C-peptide ) , glycosylated hemoglobin ( HbA1c ) , genetic typing , T lymphocyte ( T cell ) responses islet antigen . The beta cell function test perform . Patients randomize either rosiglitazone glyburide . All patient encourage perform self blood glucose monitoring twice per day , breakfast dinner . The treatment goal patient : breakfast dinner blood sugar level 90-130 milligram per deciliter ( mg/dI ) HbA1c le 7 % without severe hypoglycemia . Patients unable reach goal monotherapy metformin ( initially ) acarbose ( secondarily ) add , evidence suggest either affect beta-cell function . The rosiglitazone treatment group commence therapy 4 milligram ( mg ) per day increase twice per day adequate glycemic control achieve . For glyburide , therapy initiate 2.5 mg morning patient maintain dose receive prior start study . The start dose raise 2.5 mg even maximum 10 mg twice day necessary achieve desire glycemic control . If adequate control , HbA1c le 7 % , achieve glyburide rosiglitazone monotherapy , metformin add dose gradually increase need tolerate maximum 1000 mg twice daily . If necessary , acarbose also use maximum dose 100 mg thrice daily need tolerate . After initiation study , patient see 1 month every 3 month 3 year . Those patient randomize rosiglitazone liver enzyme alanine transaminase ( ALT ) monitor every 2 month . In addition , telephone contact utilized achieve maintain glycemic goal . Each participant follow 3 year . Drs . Chiu Palmer coordinate study . If patient his/her private physician prefer , treatment protocol implement patient 's private physician .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Age onset diabetes 3569 year old . No history ketonuria ketoacidosis . Not require insulin achieve glycemic control . Not receive two oral hypoglycemic agent . Not take thiazolidinedione agent . HbA1c establish patient ( oral hypoglycemia agent 4 month ) great 6 % 10 % . Fasting cpeptide great equal 0.8 ng/ml . Women must either postmenopausal adequate birth control ( i.e . oral contraceptive , tubal ligation , hysterectomy , condom , diaphragm ) use abstinence . Patients history chronic pancreatitis secondary cause diabetes . Patients receive systemic corticosteroid . Patients severe systemic illness ( e.g . recent MI , CHF cerebral vascular disease ) . Creatinine great 1.4 liver enzymes great 2 time upper limit normal . Not able adhere protocol .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>autoantibody</keyword>
	<keyword>islet protein</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>glyburide</keyword>
	<keyword>c-peptide</keyword>
</DOC>